Albumin binding improves nanobody pharmacokinetics for dual-modality PET/NIRF imaging of CEACAM5 in colorectal cancer models.

Incorporation of ABDs into nanobodies will enable the fusion proteins simultaneously binding to endogenous albumin, thereby extending their cycle time and increasing tumor uptake, leading to improved imaging contrast [[21]]. SP 177 sp Lu-MIRC213-709 has demonstrated excellent tumor uptake and prolonged blood circulation time, with a tumor uptake of 6.59 ± 1.67, 27.65 ± 7.66, 30.82 ± 7.29, 19.95 ± 1.76, and 17.61 ± 2.63 %ID/g at 1, 24, 48, 72, and 120 h post-injection, respectively ( I n i = 4). Another promising strategy involves fusing nanobodies with an albumin-binding domain (ABD) to extend their cycle time and increase tumor uptake, leading to improved imaging contrast [[16]]. [Extracted from the article]